{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:32:41Z","timestamp":1795059161175,"version":"4.10.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Based on current guidelines, surgical treatment of hepatic oligometastases in patients with pancreatic ductal adenocarcinoma (PDAC) is not primarily recommended. Systematic chemotherapy is the therapy of choice for these patients. The relevance of subsequent surgical resection after chemotherapy remains unclear. This multicentre, randomized, controlled phase III trial is planned to evaluate whether resection of the primary tumor and liver metastases can improve overall survival in patients with PDAC with hepatic oligometastases in a multimodal treatment setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After an induction therapy with eight cyles of mFOLFIRINOX and a response assessment after four and eight cycles, patients will be randomized to either Arm 1 (perioperative mFOFIRINOX plus resection of the primary tumor with resection or ablation of all hepatic metastases) or Arm 2 (continuation of 4 cycles of the standard-of-care mFOLFIRINOX chemotherapy). This clinical trial will focus on a well-defined patient group with metastatic disease limited to the liver as the target organ, with a maximum of three metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>METAPANC is the first international, randomized, controlled, open-label, multicentre, phase III clinical trial for curative intended surgical therapy of oligometastatic pancreatic cancer in Europe and America. The multimodal surgical treatment of patients with oligometastatic pancreatic cancer could significantly extend the overall survival of this patient group. A possible recommendation of this multimodal treatment regimen outside of clinical trials requires data from randomized controlled trials first. To identify patient subgroups that might benefit from multimodal surgical therapy, additional information on tumor genetics could supplement valid parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>EU Clinical Trials No. 2023-503558-10-00.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-13573-7","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T04:39:39Z","timestamp":1738816779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Michael","family":"Ghadimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Pelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Besselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Telgmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickmer","family":"Braren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Crede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven Thorsten","family":"Liffers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Antweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Uijterwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Seppanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno","family":"Nordin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauli","family":"Puolakkainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav F.","family":"Dajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut J\u00f8rgen","family":"Labori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein Olav","family":"Bratlie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"13573_CR1","doi-asserted-by":"publisher","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923. PMID: 21561347.","DOI":"10.1056\/NEJMoa1011923"},{"key":"13573_CR2","doi-asserted-by":"publisher","unstructured":"Kandel P, Wallace MB, Stauffer J, Bolan C, Raimondo M, Woodward TA, Gomez V, Ritter AW, Asbun H, Mody K. Survival of patients with oligometastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: a pilot study. J Pancreat Cancer. 2018;4(1):88\u201394. https:\/\/doi.org\/10.1089\/pancan.2018.0011. PMID: 30631861.","DOI":"10.1089\/pancan.2018.0011"},{"key":"13573_CR3","doi-asserted-by":"publisher","unstructured":"Renz BW, Boeck S, Roeder F, Trumm C, Heinemann V, Werner J. Oligometastatic disease in pancreatic cancer: how to proceed? Visc Med. 2017;33(1):36\u201341. https:\/\/doi.org\/10.1159\/000455027. PMID: 28612015.","DOI":"10.1159\/000455027"},{"key":"13573_CR4","doi-asserted-by":"publisher","unstructured":"Wei M, Shi S, Hua J, Xu J, Yu X, Chinese Study Group for Pancreatic Cancer (CSPAC). Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open. 2019;9(12):e033452. https:\/\/doi.org\/10.1136\/bmjopen-2019-033452. PMID: 31818843.","DOI":"10.1136\/bmjopen-2019-033452"},{"key":"13573_CR5","doi-asserted-by":"publisher","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1809775. PMID: 30575490.","DOI":"10.1056\/NEJMoa1809775"},{"key":"13573_CR6","doi-asserted-by":"publisher","unstructured":"Tong H, Fan Z, Liu B et al. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep. 2018;8:8666. https:\/\/doi.org\/10.1038\/s41598-018-26811-9. PMID: 29875415.","DOI":"10.1038\/s41598-018-26811-9"},{"key":"13573_CR7","doi-asserted-by":"publisher","unstructured":"Stegherr R, Schmoor C, Beyersmann J et al. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)\u2014estimation of adverse event risks. Trials 22, 420 (2021). https:\/\/doi.org\/10.1186\/s13063-021-05354-x. PMID: 34187527.","DOI":"10.1186\/s13063-021-05354-x"},{"key":"13573_CR8","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Krebshilfe D. AWMF). S3-Leitlinie Exokrines Pankreaskarzinom, Langversion 3.1, 2024, AWMF-Registernummer: 032-010OL [Internet]. 2024 [cited 2024 Dec 1]. Available from: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/pankreaskarzinom\/"},{"key":"13573_CR9","doi-asserted-by":"publisher","unstructured":"Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(8):1083\u201393. https:\/\/doi.org\/10.6004\/jnccn.2014.0106. PMID: 25099441.","DOI":"10.6004\/jnccn.2014.0106"},{"key":"13573_CR10","doi-asserted-by":"publisher","unstructured":"Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43(3):358\u201363. https:\/\/doi.org\/10.1016\/j.ejso.2016.10.023. PMID: 27856064.","DOI":"10.1016\/j.ejso.2016.10.023"},{"issue":"1","key":"13573_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.hpb.2019.05.015","volume":"22","author":"J Yang","year":"2020","unstructured":"Yang J, Zhang J, Lui W, Huo Y, Fu X, Yang M, et al. Patients with hepatic oligometastatic pancreatic body\/tail ductal adenocarcinoma may benefit from synchronous resection. HPB (Oxford). 2020;22(1):91\u2013101. PMID: 31262486.","journal-title":"HPB (Oxford)"},{"key":"13573_CR12","doi-asserted-by":"publisher","unstructured":"Damanakis AI, Ostertag L, Waldschmidt D, Kutting F, Quaas A, Plum P et al. Proposal for a definition of \u2018Oligometastatic disease in pancreatic cancer\u2019. BMC Cancer. 2019;19(1):1261. https:\/\/doi.org\/10.1186\/s12885-019-6448-9. PMID: 31888547.","DOI":"10.1186\/s12885-019-6448-9"},{"key":"13573_CR13","doi-asserted-by":"publisher","unstructured":"Kim Y, Kim SC, Song KB, Kim J, Kang DR, Lee JH et al. Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma. HPB. 2016;18(3):325\u201331. https:\/\/doi.org\/10.1016\/j.hpb.2015.10.014. PMID: 27037201.","DOI":"10.1016\/j.hpb.2015.10.014"},{"key":"13573_CR14","doi-asserted-by":"publisher","unstructured":"Lowder CY, Metkus J, Epstein J, Kozak GM, Lavu H, Yeo CJ et al. Clinical implications of extensive lymph node metastases for resected pancreatic cancer. Ann Surg Oncol. 2018;25(13):4004\u201311. https:\/\/doi.org\/10.1245\/s10434-018-6763-4. PMID: 30225835.","DOI":"10.1245\/s10434-018-6763-4"},{"key":"13573_CR15","doi-asserted-by":"publisher","unstructured":"Tachezy M, Gebauer F, Janot M, Uhl W, Zerbi A, Montorsi M et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160(1):136\u201344. https:\/\/doi.org\/10.1016\/j.surg.2016.02.019. PMID: 27048934.","DOI":"10.1016\/j.surg.2016.02.019"},{"key":"13573_CR16","doi-asserted-by":"publisher","unstructured":"Shi HJ, Jin C, Fu DL. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: diagnosis and assessment of unresectability. World J Gastroenterol. 2016;22(45):10024\u201337. https:\/\/doi.org\/10.3748\/wjg.v22.i45.10024. PMID: 28018110.","DOI":"10.3748\/wjg.v22.i45.10024"},{"key":"13573_CR17","doi-asserted-by":"publisher","unstructured":"Kandel P, Wallace MB, Stauffer J, Bolan C, Raimondo M, Woodward TA et al. Survival of patients with oligometastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: a pilot study. J Pancreat Cancer. 2018;4(1):88\u201394. https:\/\/doi.org\/10.1089\/pancan.2018.0011. PMID: 30631861.","DOI":"10.1089\/pancan.2018.0011"},{"key":"13573_CR18","doi-asserted-by":"publisher","unstructured":"Crippa S, Bittoni A, Sebastiani E, Partelli S, Zanon S, Lanese A et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42(12):1533\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2016.06.398. PMID: 27423449.","DOI":"10.1016\/j.ejso.2016.06.398"},{"key":"13573_CR19","doi-asserted-by":"publisher","unstructured":"Gebauer F, Damanakis AI, Bruns C. [Oligometastasis in pancreatic cancer: current state of knowledge and spectrum of local therapy]. Chirurg. 2018;89(6):510\u20135. https:\/\/doi.org\/10.1007\/s00104-018-0626-1. PMID: 29557488.","DOI":"10.1007\/s00104-018-0626-1"},{"key":"13573_CR20","doi-asserted-by":"publisher","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369. PMID: 24131140.","DOI":"10.1056\/NEJMoa1304369"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13573-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13573-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13573-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T04:39:46Z","timestamp":1738816786000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13573-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13573"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13573-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5815668\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"12 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"METAPANC is a phase III clinical trial implemented and reported in accordance with the CTR (EU) 536\/2014, ICH-GCP, with applicable member states regulations, and with the ethical principles laid down in the Declaration of Helsinki. It was submitted, evaluated, and approved via CTIS with Germany as the reporting member state. A statement of ethical approval and consent was issued by the State Office for Health and Social Affairs (LAGESO) Berlin, Germany. The ethic committee of the federal state of Berlin approved the study. METAPANC is registered under its EU Clinical Trial Number 2023-503558-10-00 in the EU Clinical Trial Register.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TF declares personal fees for statistical consultancies (including data monitoring committees) from Actimed, Apellis, Aslan, AstraZeneca, Bayer, BiosenseWebster, BMS, Cardior, CSL Behring, Daiichi Sankyo, Enanta, Fresenius Kabi, Galapagos, IQVIA, Immunic, KyowaKirin, LivaNova, Minoryx, Novartis, PINK! gegen Brustkrebs, PPD, RECARDIO, Recordati, Relaxera, Roche, Servier, Viatris, Vifor, VICO Therapeutics; all outside the submitted work.All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}